Human immunodeficiency virus (HIV) has now transformed into a manageable chronic condition. Highly active antiretroviral therapy (HAART) has proven efficacious at controlling the disease progression. Based on compelling evidence, the Department of Health and Human Services (DHHS) and the Infectious Disease Society of America (IDSA) developed guidelines for the management of persons infected with HIV. However, there are approximately 50 000 new cases of HIV in the United States each year. In this article, we review proactive methods to reduce the transmission of HIV, which include reinforcing patient education, gelcoated condoms that destroy HIV, HIV vaccinations, and adequately utilizing pre-exposure prophylaxis (PrEP), and post-exposure prophylaxis (PEP). Further development and consistent utilization of innovative prevention tools can significantly reduce the incidence of HIV infections regardless of HIV status.
Introduction
Once dubbed "The Grim Reaper" of the 1980s, human immunodeficiency virus (HIV) has now transformed into a manageable chronic condition. According to the Centers for Disease Control (CDC), there were approximately 44 073 new diagnoses of HIV in the United States in 2014. 1 Years of research and medical advancements have yielded the necessary knowledge and management strategies to keep the virus under control and, consequently, increased the patient's chance of having a life span similar to an uninfected individual. Although highly active antiretroviral therapy (ART) has proven efficacious at controlling the disease in approximately 37% of the more than 1.2 million people in the United States currently living with HIV, strategically identifying methods to reduce transmission risk may significantly diminish the future need of complex regimens. Figure 1 depicts a breakdown of the 1.2 million Americans living with HIV to differentiate among those who are diagnosed with the virus, linked to care, engaged in care, prescribed ART, and those who achieve viral suppression. 2 HIV can be transmitted when certain body fluids (blood, vaginal/seminal fluids, rectal fluid, or breast milk) from an HIV-infected individual are introduced into the bloodstream or through mucus membranes and damaged skin surfaces. The CDC estimates that there are approximately 4 transmissions per year for every 100 individuals living with HIV. 1 When patients are compliant with medications, practice safe sex, and incorporate healthy lifestyle modifications, the majority of individuals living with HIV will have a decreased incidence of transmitting the virus; however, the CDC reports that at least 16% of patients who come in contact with the virus are not aware of their infection. 3 This uncertainty accounts for at least half of the estimated 44 073 new HIV infections each year. 1 Although HIV testing rates have improved and can detect the virus in earlier stages of transmission, more than half of Americans do not receive an HIV test during their lifetime. 4 Being unaware of one's HIV status is an important risk for transmitting the virus. If HIV is stopped at the source of transmission, it is highly possible that the incidence of HIV will drastically decrease and the virus may potentially meet its demise. This article will explore various current and developmental prevention strategies utilized to reduce further transmission of HIV.
Patient Education
With any disease state, it is imperative that pharmacists and other health-care professionals assess, reaffirm, and provide additional education to adequately manage the disease. There are numerous preconceived notions that both patients and the general public have about HIV and its transmission. The CDC has several campaigns (eg, HIV Screening Standard Care, Prevention IS Care, and One Test Two Lives) with provider tool kits to educate patients on a variety of topics. HIV Screening Standard Care is aimed at encouraging universal HIV testing for patients during routine medical visits. A resource center has been developed in partnership with the American Journal of Medicine, which provides materials, interactive videos, and displays continuing medical education events for providers. 5 Prevention IS Care encourages the provider to initiate "small talks" into every office visit. These "small talks" should focus on ART adherence and safer sexual practices. Resources include educational brochures, wall posters, and continuing medical programs to help retain patients in care, increase ART initiation and adherence, as well as avoid coinfections and sexually transmitted infections (STIs). 5 One Test Two Lives places focus on women, so that they are tested early in their pregnancy in order to prevent perinatal transmission. Therefore, resources are available to obstetric providers in the form of brochures, posters, fact sheets, and a due date projection wheel to highlight the optimal time to test a pregnant woman. 5 Abstain, Be Faithful, and Use Condoms
In the United States, approximately 75% of both males and females have encountered a sexual experience by the age of 20 ( Figure 2) . 6 Abstinence from oral, vaginal, or anal intercourse provides 100% protection from sex-related transmission of HIV infection. 7 The "Compendium of Evidence-Based Interventions and Best Practices for HIV Prevention" has several studies that have shown promising results to increase abstinence and reduce sexual activity in high-risk teenagers. Assisting in Rehabilitating Kids and Becoming a Responsible Teen are 2 interventions that have utilized the Information-Motivation-Behavior model to deliver games, group discussions, lectures, and role playing to participants. 8 Despite the fact that abstinence is an important method for the prevention of HIV transmission and should be encouraged, there are also circumstances (eg, nonconsensual) where abstinence is unavoidable. Sixty-two percent of female respondents who had sex by their 10th birthday reported that their first experience was nonconsensual. 6 Abstinence is sometimes impractical to individuals; therefore, romantic relationships in which both partners are monogamous and aware of their negative HIV status are a safer alternative. Monogamy should clearly defined in any relationship. A study conducted in the Journal of Sex Research concluded that monogamy was left to interpretation in 40% of the 434 couples interviewed, meaning there was no explicit agreement on whether being faithful was expected. 9 Another retrospective study evaluating 134 HIVinfected women in South India that predominately (89%) reported single-partner heterosexual intercourse with their husbands as their only HIV risk factor also supports the need for increased education on the importance of mutual monogamy. 10 Although the study population's self-perception of HIV infection risk was low, these women were inadvertently at risk due to the potential actions of their husbands. Married couples are further at risk due to infrequent use of condoms for a variety of reasons including a desire to have children. 11 Decreased awareness, reduced condom use, and lack of adequate communication may all present barriers to the traditional recommendation of being in a long-term relationship with a single partner in order to prevent HIV infection.
When used correctly and frequently, male condoms have shown to be approximately 80% to 95% effective in decreasing the risk of HIV transmission. 12 Inappropriate use (ie, using 2 Because it is calculated differently from other steps in the continuum, it cannot be directly compared to other steps and is therefore shown in a different color. 47 condoms at once, incorrectly applying the condom) can increase the risk of exposure and transmission. Although condoms come in a variety of styles, material makeup, shapes, sizes, and flavors, patients should be aware that lambskin condoms do not effectively protect against HIV transmission because the pores are large enough to permit the passage of the virus. 13 Starpharma has developed a polyanion-based, entry inhibitor, topical microbicide called astodrimer sodium (VivaGel1), which provides antiviral protection not only against HIV but also against herpes simplex virus (HSV).
14,15 Potent antiviral activity was observed and sustained for at least 3 hours against HIV-1 and HSV-2 immediately after vaginal application. 15 VivaGel-coated condoms have gained approval in Australia and are currently being marketed under the brand Lifestyle Dual Protect1. 16 It is unclear whether these VivaGel-coated condoms will be useful in men who have sex with men (MSMs) due to the differences in the vaginal and rectal linings, but they may make an alternative choice for preventative measures.
HIV Testing/Screening
Acute HIV infection (initial 10-12 weeks) accounts for about 10% to 50% of HIV transmissions because patients generally have a high viral load but are unaware they have become infected. 17 The US Preventative Services Task Force recommends that HIV screening becomes a part of routine clinical care for patients aged 15 to 65 years and for all pregnant women. 18 At least yearly retesting is recommended for patients who participate in high-risk behavior like sharing needles and unprotected anal or vaginal sex. 18 Several types of HIV screening tools are available, including home sampling and testing kits. The most common HIV test analyzes blood (eg, Home Access System1) or oral fluid samples from the gumline (eg, OraQuick1) utilizing an enzyme-linked immunosorbent assay or enzyme immunoassay. 19 Laboratory analysis may take up toFourth-generation tests are the preferred assays in all HIV screenings. 22 This assay is useful in diagnosing HIV infection because it not only identifies HIV-1/HIV-2 antibodies but also an HIV-specific antigen, surface protein p24. 23 Surface protein p24 is quantifiable prior to seroconversion and allows for more rapid HIV detection (median, 5-7 days) compared to thirdgeneration tests, which only detect HIV-1/HIV-2 antibodies. 23 Third-generation assays are useful but would require an appropriate interpretation of the results. A negative or nonreactive test result cannot rule out acute infections (ie, preseroconversion). 23 A positive or reactive test would require a Western blot for confirmation; however, if patients are in early seroconversion, results may be indeterminate or negative. 19 This scenario could delay HIV diagnosis. 23 If confirmatory testing yields a positive result, patients should be linked to medical care as soon as possible. 24 Regardless of test results, patients should be educated on the importance of practicing safe sex and positive risk reduction modifications. 
Pre-Exposure Prophylaxis
Both HIV-positive and HIV-negative individuals engage in sexual activities that may put them at risk for acquiring or transmitting the disease. Pre-exposure prophylaxis (PrEP) is a pharmacotherapeutic strategy, which can help prevent the transmission of HIV in noninfected individuals who engage in high-risk activities with an increased chance of acquiring HIV. 25 In 2014, approximately 24.7% of sexually active MSMs, 18.5% of injection drug users (IDUs), and 0.4% of heterosexually active adults had substantial risks for acquiring HIV consistent with PrEP indications. 26 The Pre-exposure Prophylaxis Initiative (iPrEx) study was a randomized clinical trial for PrEP, which investigated once-daily tenofovir disoproxil fumarate/emtricitabine among men and maleto-female transgender adults. Participants reported sex with a man during the 6 months prior to enrollment. iPrEx study results demonstrated that tenofovir disoproxil fumarate/emtricitabine reduced HIV acquisition by 73% when patients reported to be greater than 90% adherent to the medication regimen. 27 This same treatment group showed the risk of acquiring HIV to be reduced by 92%, if there was detectable plasma and intracellular levels of tenofovir disoproxil fumarate/emtricitabine. 27 In the Partners PrEP trial, tenofovir disoproxil fumarate/emtricitabine and tenofovir disoproxil fumarate demonstrated an efficacy of 75% and 67%, respectively, when given to uninfected partners in HIV-discordant heterosexual couples. 28 In the On Demand Antiretroviral Preexposure Prophylaxis for HIV Infection in Men Who Have Sex With Men study, an "on-demand" PrEP protocol was used that instructed participants to take tenofovir disoproxil fumarate/emtricitabine with food at specified intervals before and after sex. Published results showed an 86% reduction in risk. 29 The combination product tenofovir disoproxil fumarate/ emtricitabine is indicated for daily use as PrEP in MSMs, IDUs, and heterosexual males and females. 25 Daily tenofovir disoproxil fumarate alone can be utilized as an alternative regimen for PrEP; however, it is only recommended for IDUs and heterosexual males and females since efficacy has not been established in the MSM population. 25 Before an individual can initiate PrEP, clinicians should make sure that they are candidates for therapy. The risk detection criteria for patients who are eligible for PrEP include the following: those patients who have an HIV-positive sexual partner (serodiscordant couple), HIV-positive injecting partner, recent bacterial STI, high number of sex partners, history of inconsistent or no condom use, commercial sex workers, and those who had recent drug treatment. 25 Clinical eligibility for PrEP in adult patients requires a documented negative HIV test result before prescribing medication, no signs/symptoms of acute HIV infection, normal renal function, no contraindicated medications, and documented hepatitis B virus (HBV) infection and vaccination status. 25 PrEP continuation is contingent upon the patient having a negative HIV test throughout the course of therapy; therefore, follow-up HIV testing should be performed quarterly. 25 Patients who initially test positive for hepatitis B surface antigen, should be screened for HBV DNA (quantitative assay) before PrEP is prescribed and every 6 to 12 months while on pharmacotherapy. 25 Because tenofovir disoproxil fumarate has the potential to cause kidney damage, patients' renal functions will also need to be monitored frequently for all patients. 30 To be most effective, PrEP must be taken daily for as long as the individual is participating in high-risk behaviors. Although PrEP is an effective tactic to reduce HIV transmission, it is not guaranteed. To date, there has been one known case of PrEP failure in adherent patients, which occurred as a result of the patient acquiring a tenofovir disoproxil fumarate/emtricitabine-resistant HIV-1 strain. 31 PrEP should be utilized in combination with methods like behavioral risk reduction counseling, which places emphasis on preventing substance abuse, condom use, support for risk reduction, and nonjudgmental behavioral monitoring. 25 New developments in PrEP have been conducted, particularly with nucleoside reverse transcriptase inhibitors, dapivirine and rilpivirine, CC chemokine receptor 5 (CCR5), inhibitor maraviroc (MVC), integrase stand inhibitor, cabotegravir, and the nucleotide reverse-transcriptase inhibitor, tenofovir disoproxil fumarate and tenofovir alafenamide (TAF). As an intravaginal ring, dapivirine has been used alone or with MVC to establish safety and tolerability. 32 Efficacy of tenofovir disoproxil fumarate (39%), formulated as a topical intravaginal gel, has been demonstrated in the Centre for the AIDS Programme of Research in South Africa (CAPRISA-004); however, studies like Vaginal and Oral Interventions to Control the Epidemic (VOICE) and Follow-on African Consortium for Tenofovir Studies (FACTS-001) have failed to show an equivalent or greater promise of efficacy. 32 TAF formulated as a subdermal implant has demonstrated sustained plasma levels in animals for up to 40 days, which could lead to further adaptation in ART and PrEP therapy. 33 Intramuscular injections of rilpivirine (rilpivirine long acting) and cabotegravir have been well tolerated and showed favorable peak concentrations. Additionally, rilpivirine LA has been shown to reach higher concentrations in rectal tissues compared to vaginal or cervical. 32 
Post-Exposure Prophylaxis
Post-exposure prophylaxis (PEP), whether occupational (oPEP) or nonoccupational (nPEP), is another prevention strategy for individuals who have had a single substantial exposure risk to confirmed or potential HIV-infected fluids. Figure 3 further explains substantial versus nonsubstantial exposure risks to help determine whether an individual is a candidate for PEP. PEP, when initiated within 72 hours of exposure, has been shown to decrease the risk of HIV transmission by up to 85%. 34 Treatment of either oPEP or nPEP consists of a regimen of 3 antiretroviral medications taken for a course of 28 days (4 weeks), followed by continuous monitoring, risk reduction counseling, and testing to ensure the individual has not seroconverted to HIV positive. 34 The preferred oPEP and nPEP regimen is tenofovir disoproxil fumarate/emtricitabine once daily plus raltegravir 400 mg twice daily; however, dolutegravir 50 mg daily can be substituted for raltegravir in nPEP. 35 Because PEP is not guaranteed to prevent infection, patients should be properly educated about various methods of risk reduction strategies to prevent secondary exposure.
Infant ART Prophylaxis
Protocols to reduce the transmission of HIV from mother to child during pregnancy, childbirth, and breast-feeding have significantly reduced the incidence of HIV cases in newborns. Without treatment, perinatal transmission can be as high as 25% to 30%. 36 In 1994, the Pediatric AIDS Clinical Trials Group reported that administering zidovudine to the mother during pregnancy and labor as well as to the infant at birth was able to decrease vertical transmission by 68%. 36 Typically, neonates born to HIV-infected mothers receive a weightbased dose of zidovudine, preferably within 6 to 12 hours of birth. 37 This therapy may last either 4 or 6 weeks depending on gestational age and whether the mother was taking a stable ART regimen during pregnancy.
37 HIV-exposed infants should also be administered 3 doses of nevirapine within the first week of life if their mother has only received intrapartum ART, has not received previous ART, or has received antepartum ART drugs but has suboptimal viral suppression (>1000 copies/mL) near delivery. 37 The CDC has set goals for 1 perinatal transmission per 100 000 live births; however, by the end of 2012, that rate was 4.6 per 100 000 with 181 cases. 38 
HIV-Medicated Tampons
Topical surfactants, polyanions, and acid-buffering microbicides have been investigated for years as a means of preventing HIV infection but have failed to produce efficacy in several studies. 39 A team of bioengineers with the University of Washington has developed an innovative approach in reducing transmission through the use of electrospun dissolvable tampons. 40 These tampons infuse the antiretroviral agent MVC with a fiber-like polymer designed to carry 10 times as much active ingredient as a comparable amount of gel. The fibers are expected to dissolve in approximately 6 minutes, thus delivering the HIV-preventing medication minutes before sexual activity. 40 MVC, the active ingredient in the tampon, is currently used as an oral HIV medication typically reserved for individuals with multiple resistance and regimen failure on standard therapies. As a CCR5 antagonist, MVC works by blocking the virus from using 1 of 2 coreceptors to enter the host cell. Although more than 80% of HIV exclusively use CCR5 as a mode of entry, approximately 16% of strands have the ability to use both CCR5 and C-X-C chemokine receptor type 4 (CXCR4) coreceptors (dual/mixed tropic virus) and 2% of the viruses exclusively use CXCR4. 41 The oral formulation of MVC (Selzentry1) requires an HIV Trofile assay to be performed prior to initiation of the medication to determine which tropism is present. MVC can be used if the virus only uses the CCR5 receptor (R5) but is ineffective against CXCR4 (X4-tropic) viruses or dual/mixed (D/M) tropic viruses. 42 Because the medication is only effective against selective HIV strains, it may be impractical as a preventative therapy when used alone without an HIV Trofile test from a positive individual. These tampons are not expected to be available for years to come, but if MVC displays adequate concentration in the genital tract as a topical product, it could be another useful agent to decrease transmission of HIV. 40 
Immunizations
Currently, there are no vaccines that will prevent individuals from acquiring HIV. For years, researchers have attempted to create a vaccine that will provide protection against the virus, but there have been numerous obstacles (Table 1 ). In addition, it is unethical to expose noninfected patients to the virus for scientific research. The concept of creating a vaccine against HIV is centered on the ability of the immune system to produce antibodies that will avert the virus from entering the host cells (adaptive immunity). The issue with developing a suitable vaccination is that antibodies may work in vitro but not against the various strains of HIV presented in infected individuals. 43 Antibodies capable of broadly neutralizing various types of HIV, called bnAbs, have shown to be effective in animals, but humans have not been able to produce the same antibody response. 44 Recently, Kong et al discovered a vulnerable target site for a bnAbs (VRC34.01) in the HIV fusion peptide, which can lead to further vaccine development. 45 
Potential HIV Cure in Progress
HIV is considered a chronic disorder because it destroys the immune system by permanently integrating its viral DNA into the host genome and continuously replicating to invade more CD4 cells. Even with successful treatment and an undetectable viral load, the virus can lie dormant in various tissues throughout the body. Dr Kamel Khalili, professor and chair of the Department of Neuroscience at Temple University School of Medicine in Philadelphia, and his research team have developed a method to genetically remove the integrated viral DNA from human cells. 46 These researchers engineered an in vitro 20-nucleotide strand of guide RNA that locates and targets long terminal repeats present on both ends of the HIV-1 viral genome and combined it with a DNA nuclease called Cas9 which edits the DNA strand by snipping the 9709-nucleotides in HIV-1 DNA from the human genome. 46 Once the viral genome has been removed, human cells repair themselves as they would in the natural DNA replication process. Barriers to clinical implementation include identifying a method to ensure delivery of the therapeutic agent to every infected cell as well as accounting for the frequent genetic mutations seen with HIV infection. Though these genetic modifying techniques remain in 
Conclusion
Though HIV, through research and medical advancement over the years, has been developed into a manageable chronic condition for most individuals, current US statistics of 44 073 new cases per year and 16% of the infected population not being aware of their status suggests that there must be a diligent fight to create an HIV/AIDS-free generation. 1, 3 Educating the general public about the disease, its modes of transmission, and how to prevent transmission remain paramount to decreasing worldwide incidences. Although HIV-positive individuals should seek immediate linkage to care for an evaluation of treatment options, at-risk HIV-negative individuals should consciously choose to preventative measures and precautions. Proactive prevention strategies, when utilized consistently, can significantly reduce the incidence of HIV infections regardless of HIV status. No prevention strategy alone is 100% effective, but when multiple approaches are combined, the risk of transmission declines exponentially.
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